Cited by 1,967Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 168 of the 169 references it cites were found in a registry or an index.

The first 30 years of p53: growing ever more complex.

Open access

Levine, Arnold J., Oren, Moshe·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen, the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 DNA and the realization that p53 is not an oncogene but a tumour suppressor that is very frequently mutated in human cancer. In the second decade of research, the function of p53 was uncovered: it is a transcription factor induced by stress, which can promote cell cycle arrest, apoptosis and senescence. In the third decade after its discovery new functions of this protein were revealed, including the regulation of metabolic pathways and cytokines that are required for embryo implantation. The fourth decade of research may see new p53-based drugs to treat cancer. What is next is anybody's guess.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc2723

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“More recently, induction of cellular senescence was identified as an additional mechanism whereby p53 curbs neoplastic processe”
p53, guardian of the genome
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Self-citation
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Self-citation
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Show all 169 references

Sorted by citations

Items 201–300 of 1,002

The function, regulation and therapeutic implications of the tumor suppressor protein, PML
Guan, D., & Kao, H. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0051-9 · Cited by 99
A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer
Gu, L., Deng, Z. J., Roy, S., & Hammond, P. T. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2186 · Cited by 99
p53 in neurodegenerative diseases and brain cancers
Checler, F., & da Costa, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.009 · Cited by 99
Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD
Zhang, C., Liu, J., Wu, R., Liang, Y., 林美华, Liu, J., Chan, C. S., Hu, W., & Feng, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2137 · Cited by 101
Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma
Liu, J., Zhang, C., Lin, M., Zhu, W. J., Liang, Y., Hong, X., Zhao, Y., Young, K. H., Hu, W., & Feng, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.1862 · Cited by 99
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Wang, J., Hu, K., Guo, J., Cheng, F., Lv, J., Jiang, W., Lü, W., Liu, J., Pang, X., & Liu, M. (2016) · Nature Communications · doi:10.1038/ncomms11363 · Cited by 97
The Interplay Between Tumor Suppressor p53 and Hypoxia Signaling Pathways in Cancer
Zhang, C., Liu, J., Wang, J., Zhang, T., Xu, D., Hu, W., & Feng, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648808 · Cited by 100
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Wang, Z., Burigotto, M., Ghetti, S., Vaillant, F., Tan, T., Capaldo, B. D., Palmieri, M., Hirokawa, Y., Tai, L., Simpson, D. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0402 · Cited by 108
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
Identification of a DNA Damage–Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers
Chen, J., Crutchley, J., Zhang, D., Owzar, K., & Kastan, M. B. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0908 · Cited by 93
Do Mutations Turn p53 into an Oncogene?
Pitolli, C., Wang, Y., Mancini, M., Shi, Y., Melino, G., & Amelio, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246241 · Cited by 97
Intrinsically Disordered p53 and Its Complexes Populate Compact Conformations in the Gas Phase
Pagel, K., Natan, E., Hall, Z., Fersht, A. R., & Robinson, C. V. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203047 · Cited by 94
Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma
Christopoulos, P., Kirchner, M., Bozorgmehr, F., Endris, V., Elsayed, M., Budczies, J., Ristau, J., Penzel, R., Herth, F. J. F., Heußel, C. P., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31893 · Cited by 93
SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism
Luna, A., Aladjem, M. I., & Kohn, K. W. (2013) · Genome Integrity · doi:10.1186/2041-9414-4-6 · Cited by 96
Endothelial pyruvate kinase M2 maintains vascular integrity
Kim, B., Jang, C., Dharaneeswaran, H., Li, J., Bhide, M., Yang, S. H., Li, K., & Arany, Z. P. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120912 · Cited by 91
Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications
Tan, H., Zhang, S., Zhang, J., Zhu, L., Chen, Y., Yang, H., Chen, Y., An, Y., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.47548 · Cited by 95
The p53 circuit board
Sullivan, K. D., Gallant‐Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.004 · Cited by 96
Identification of miR-30d as a novel prognostic maker of prostate cancer
Kobayashi, N., Uemura, H., Nagahama, K., Okudela, K., Furuya, M., Ino, Y., Ito, Y., Hirano, H., Inayama, Y., Aoki, I., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.696 · Cited by 95
Meiotic Recombination Provokes Functional Activation of the p53 Regulatory Network
Lu, W.-J., Chapo, J. A., Roig, I., & Abrams, J. (2010) · Science · doi:10.1126/science.1185640 · Cited by 94
The interplay of NR4A receptors and the oncogene–tumor suppressor networks in cancer
Beard, J. A., Tenga, A., & Chen, T. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.11.009 · Cited by 94
p53 Searches on DNA by Rotation-Uncoupled Sliding at C-Terminal Tails and Restricted Hopping of Core Domains
Terakawa, T., Kenzaki, H., & Takada, S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305369u · Cited by 91
Human cancer databases (Review)
Pavlopoulou, A., Spandidos, D. A., & Michalopoulos, I. (2014) · Oncology Reports · doi:10.3892/or.2014.3579 · Cited by 97
TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)
Tornesello, M. L. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5448 · Cited by 105
ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis
Okochi‐Takada, E., Hattori, N., Tsukamoto, T., Miyamoto, K., Ando, T., Ito, S., Yamamura, Y., Wakabayashi, M., Nobeyama, Y., & Ushijima, T. (2013) · Oncogene · doi:10.1038/onc.2013.174 · Cited by 91
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C.-C., Suárez, C., Vos, F. D., Steeghs, N., Cassier, P. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1295 · Cited by 91
Sonoporation Induces Apoptosis and Cell Cycle Arrest in Human Promyelocytic Leukemia Cells
Zhong, W., Sit, W. H., Wan, J. M. F., & Yu, A. C. H. (2011) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2011.09.012 · Cited by 89
Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators
Bertamino, A., Soprano, M., Musella, S., Rusciano, M. R., Sala, M., Vernieri, E., Sarno, V. D., Limatola, A., Carotenuto, A., Cosconati, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400311n · Cited by 86
The Regulation of Aging and Longevity: A New and Complex Role of p53
Feng, Z., Lin, M., & Wu, R. (2011) · Genes & Cancer · doi:10.1177/1947601911410223 · Cited by 88
p53 and the Viral Connection: Back into the Future ‡
Aloni-Grinstein, R., Charni‐Natan, M., Solomon, H., & Rotter, V. (2018) · Cancers · doi:10.3390/cancers10060178 · Cited by 88
A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85
p53, a translational regulator: contribution to its tumour-suppressor activity
Marcel, V., Catez, F., & Diaz, J. (2015) · Oncogene · doi:10.1038/onc.2015.25 · Cited by 94
The Methyltransferase Set7/9 (Setd7) Is Dispensable for the p53-Mediated DNA Damage Response In Vivo
Campaner, S., Spreafico, F., Burgold, T., Doni, M., Rosato, U., Amati, B. B., & Testa, G. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.007 · Cited by 88
Development and translational imaging of a TP53 porcine tumorigenesis model
Sieren, J. C., Meyerholz, D. K., Wang, X., Davis, B. T., Newell, J. D., Hammond, E., Rohret, J. A., Rohret, F., Struzynski, J. T., Goeken, J. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75447 · Cited by 88
Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells
Stone, O. A., El-Brolosy, M. A., Wilhelm, K., Liu, X., Romão, A. M., Grillo, E., Lai, J. K. H., Günther, S., Jeratsch, S., Kuenne, C. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06406-8 · Cited by 91
The Histone Lysine Demethylase JMJD3/KDM6B Is Recruited to p53 Bound Promoters and Enhancer Elements in a p53 Dependent Manner
Williams, K., Christensen, J. F., Rappsilber, J., Nielsen, A. L., Johansen, J. V., & Helin, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096545 · Cited by 91
Li–Fraumeni Syndrome
Correa, H. (2016) · Journal of Pediatric Genetics · doi:10.1055/s-0036-1579759 · Cited by 89
Liver and Steroid Hormones—Can a Touch of p53 Make a Difference?
Charni‐Natan, M., Aloni-Grinstein, R., Osher, E., & Rotter, V. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00374 · Cited by 91
Gain-of-function mutant p53: history and speculation
Bargonetti, J., & Prives, C. L. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz067 · Cited by 87
A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly
Krastev, D. B., Slabicki, M. M., Paszkowski‐Rogacz, M., Hubner, N. C., Junqueira, M., Shevchenko, A., Mann, M., Neugebauer, K. M., & Buchholz, F. (2011) · Nature Cell Biology · doi:10.1038/ncb2264 · Cited by 88
p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLθ pathways
Roy, S., Tomaszowski, K.-H., Luzwick, J. W., Park, S., Li, J., Murphy, M. E., & Schlacher, K. (2018) · eLife · doi:10.7554/elife.31723 · Cited by 88
miR-661 downregulates both Mdm2 and Mdm4 to activate p53
Hoffman, Y., Bublik, D. R., Pilpel, Y., & Oren, M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.146 · Cited by 88
Self-citation
Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages
Jiang, D., Brady, C. A., Johnson, T. M., Lee, E. Y., Park, E. J., Scott, M. P., & Attardi, L. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111245108 · Cited by 90
Rbm24, a target of p53, is necessary for proper expression of p53 and heart development
Zhang, M., Zhang, Y., Xu, E., Mohibi, S., de Anda, D. M., Jiang, Y., Zhang, J., & Chen, X. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-017-0029-8 · Cited by 85
Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer
Chen, D., Guo, Z., Yao, L., Sun, Y., Dian, Y., Zhao, D., Ke, Y., Zeng, F., Zhang, C., Deng, G., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103686 · Cited by 95
Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore
Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 86
Opportunities and challenges in combination gene cancer therapy
Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85
Unraveling the Guardian: p53’s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies
Zhang, H., Xu, J., Long, Y., Maimaitijiang, A., Su, Z., Li, W., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312928 · Cited by 97
MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3′ untranslated region
Tian, S., Huang, S., Wu, S., Guo, W., Li, J., & He, X. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.112 · Cited by 86
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia
Long, J., Parkin, B. L., Ouillette, P. D., Bixby, D. L., Shedden, K., Erba, H. P., Wang, S., & Malek, S. N. (2010) · Blood · doi:10.1182/blood-2010-01-261628 · Cited by 87
The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA
Weingarten-Gabbay, S., Khan, D., Liberman, N., Yoffe, Y., Bialik, S., Das, S., Oren, M., & Kimchi, A. (2013) · Oncogene · doi:10.1038/onc.2012.626 · Cited by 91
Self-citation
Pharmacological blockade of a β2AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model
Hara, M. R., Sachs, B. D., Caron, M. G., & Lefkowitz, R. J. (2013) · Cell Cycle · doi:10.4161/cc.23368 · Cited by 87
The real war on cancer: the evolutionary dynamics of cancer suppression
Nunney, L. (2012) · Evolutionary Applications · doi:10.1111/eva.12018 · Cited by 83
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer
Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J., & Carpizo, D. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.006 · Cited by 83
Self-citation
PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer
Lee, K.-H., Park, J.-W., Sung, H.-S., Choi, Y.-J., Kim, W., Lee, H. S., Chung, H.-J., Shin, H.-W., Cho, C.-H., Kim, T.-Y., et al. (2014) · Oncogene · doi:10.1038/onc.2014.219 · Cited by 89
Distinct p53 genomic binding patterns in normal and cancer-derived human cells
Botcheva, K., McCorkle, S., McCombie, W. R., Dunn, J. J., & Anderson, C. W. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18383 · Cited by 84
The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?
Moulder, D. E., Hatoum, D., Tay, E. S. E., Lin, Y., & McGowan, E. M. (2018) · Cancers · doi:10.3390/cancers10060189 · Cited by 87
A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development
Shi, D., & Jiang, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762651 · Cited by 84
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System
Abbas, R., & Larisch, S. (2021) · Cells · doi:10.3390/cells10123465 · Cited by 91
Regulation of Metabolic Activity by p53
Flöter, J., Kaymak, I., & Schulze, A. (2017) · Metabolites · doi:10.3390/metabo7020021 · Cited by 81
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4
Polotskaia, A., Xiao, G., Reynoso, K., Martin, C., Qiu, W., Hendrickson, R. C., & Bargonetti, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416318112 · Cited by 83
Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2
Wang, W., Zhang, X., Qin, J., Voruganti, S., Nag, S. A., Wang, M., Wang, H., & Zhang, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041586 · Cited by 81
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
Hiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81
BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function
Yue, X., Zhao, Y., Liu, J., Zhang, C., Yu, H., Wang, J., Zheng, T., Liu, L., Li, J., Feng, Z., et al. (2015) · eLife · doi:10.7554/elife.08401 · Cited by 81
ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome
Tavares, C., Melo, M., Cameselle‐Teijeiro, J., Soares, P., & Sobrinho-Simões, M. A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0605 · Cited by 86
TP53 and MTOR crosstalk to regulate cellular senescence
Galluzzi, L., Kepp, O., & Kroemer, G. (2010) · Aging · doi:10.18632/aging.100202 · Cited by 83
An Ultrahigh Affinity d -Peptide Antagonist Of MDM2
Zhan, C., Zhao, L., Wei, X., Wu, X., Chen, X., Yuan, W., Lu, W., Pazgier, M., & Lu, W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3005465 · Cited by 80
TRAF6 Restricts p53 Mitochondrial Translocation, Apoptosis, and Tumor Suppression
Zhang, X., Li, C., Zhang, L., Wu, C., Han, L., Jin, G., Rezaeian, A. H., Han, F., Liu, C., Xu, C. S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.002 · Cited by 81
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 84
Colorectal cancer triple co-culture spheroid model to assess the biocompatibility and anticancer properties of polymeric nanoparticles
Bauleth-Ramos, T., Feijão, T., Gonçalves, A., Shahbazi, M.-A., Liu, Z., Barrias, C., Oliveira, M. J., Granja, P., Santos, H. A., & Sarmento, B. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.025 · Cited by 79
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
Zhao, C. Y., Grinkevich, V., Nikulenkov, F., Bao, W., & Selivanova, G. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11545 · Cited by 79
Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response
Porter, J. R., Fisher, B. E., Baranello, L., Liu, J. C., Kambach, D. M., Nie, Z., Koh, W. S., Luo, J., Stommel, J. M., Levens, D., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.028 · Cited by 79
Therapeutic Insights on Ferroptosis in Parkinson's disease
Thapa, K., Khan, H., Kanojia, N., Singh, T. G., Kaur, A., & Kaur, G. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175133 · Cited by 76
Dynamics of p53: A Master Decider of Cell Fate
Luo, Q., Beaver, J. M., Liu, Y., & Zhang, Z. (2017) · Genes · doi:10.3390/genes8020066 · Cited by 78
p53 mediates loss of hematopoietic stem cell function and lymphopenia in Mysm1 deficiency
Belle, J. I., Langlais, D., Petrov, J. C., Pardo, M., Jones, R. G., Gros, P., & Nijnik, A. (2015) · Blood · doi:10.1182/blood-2014-05-574111 · Cited by 77
Single‐cell transcriptomes reveal heterogeneity of high‐grade serous ovarian carcinoma
Hao, Q., Li, J., Zhang, Q., Xu, F., Xie, B., Lu, H., Wu, X., & Zhou, X. Y. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.500 · Cited by 76
Transcription Factor YY1 Contributes to Tumor Growth by Stabilizing Hypoxia Factor HIF-1α in a p53-Independent Manner
Wu, S., Kasim, V., Kano, M. R., Tanaka, S., Ohba, S., Miura, Y., Miyata, K., Liu, X., Matsuhashi, A., Chung, U., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0366 · Cited by 78
cncRNAs: Bi-functional RNAs with protein coding and non-coding functions
Kumari, P., & Sampath, K. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.024 · Cited by 77
Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator
Zhou, X. Y., Hao, Q., Liao, P., Luo, S., Zhang, M., Hu, G., Liu, H., Zhang, Y.-W., Cao, B., Baddoo, M., et al. (2016) · eLife · doi:10.7554/elife.15099 · Cited by 84
The evolution of thymic lymphomas in p53 knockout micePreprint
Dudgeon, C., Chan, C. H., Kang, W., Sun, Y., Emerson, R., Robins, H. S., & Levine, A. J. (2014) · Genes & Development · doi:10.1101/gad.252148.114 · Cited by 77
Self-citation
p53 protects against LPS-induced lung endothelial barrier dysfunction
Barabutis, N., Dimitropoulou, C., Birmpas, C., Joshi, A., Thangjam, G. S., & Catravas, J. D. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00334.2014 · Cited by 76
Apoptosis in inner ear sensory hair cells
Morrill, S., & He, D. Z. Z. (2017) · Journal of Otology · doi:10.1016/j.joto.2017.08.001 · Cited by 78
Ubiquitin ligases in cancer: Functions and clinical potentials
Duan, S., & Pagano, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.008 · Cited by 77
Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53
Li, J., Lama, R., Galster, S. L., Inigo, J. R., Wu, J., Chandra, D., Chemler, S. R., & Wang, X. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0728 · Cited by 80
Inactivation and Inducible Oncogenic Mutation of p53 in Gene Targeted Pigs
Leuchs, S., Saalfrank, A., Merkl, C., Flisikowska, T., Edlinger, M., Durkovic, M., Rezaei, N., Kurome, M., Zakhartchenko, V., Kessler, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043323 · Cited by 76
Chromosomal Instability Associated with Global DNA Hypomethylation is Associated with the Initiation and Progression of Esophageal Squamous Cell Carcinoma
Kawano, H., Saeki, H., Kitao, H., Tsuda, Y., Otsu, H., Ando, K., Ito, S., Egashira, A., Oki, E., Morita, M., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3818-z · Cited by 76
Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival
Bublik, D. R., Bursać, S., Sheffer, M., Oršolić, I., Shalit, T., Tarcic, O., Kotler, E., Mouhadeb, O., Hoffman, Y., Fuchs, G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614876114 · Cited by 77
Self-citation
Combined experimental and computational analysis of DNA damage signaling reveals context‐dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress
Tentner, A. R., Lee, M. J., Ostheimer, G. J., Samson, L. D., Lauffenburger, D. A., & Yaffe, M. B. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.1 · Cited by 74
An update on the central nervous system manifestations of Li–Fraumeni syndrome
Orr, B. A., Clay, M. R., Pinto, E. M., & Kesserwan, C. A. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02055-3 · Cited by 80
Jumonji histone demethylases as emerging therapeutic targets
Park, S. Y., Park, J., & Chun, Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.026 · Cited by 75
Essential Roles of E3 Ubiquitin Ligases in p53 Regulation
Sane, S., & Rezvani, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020442 · Cited by 78
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis
Wang, G., Chan, C., Gao, Y., & Lin, H. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10319 · Cited by 75
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
Li, X., Wu, B. J., Chung, L. W. K., & Huang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.5879 · Cited by 73
Role ofTP53mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
Darb‐Esfahani, S., Denkert, C., Stenzinger, A., Salat, C., Sinn, B. V., Schem, C., Endris, V., Klare, P., Schmitt, W., Blohmer, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11891 · Cited by 80
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Soussi, T. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00005-0 · Cited by 77
CDK 2 positively regulates aerobic glycolysis by suppressing SIRT 5 in gastric cancer
Tang, Z., Li, L., Tang, Y., Xie, D., Wu, K., Wei, W., & Xiao, Q. (2018) · Cancer Science · doi:10.1111/cas.13691 · Cited by 71
Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
Maerken, T. V., Rihani, A., Dreidax, D., Clercq, S. D., Yigit, N., Marine, J., Westermann, F., Paepe, A. D., Vandesompele, J., & Speleman, F. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1090 · Cited by 72
Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics
Lee, A. J. X., & Swanton, C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.008 · Cited by 70
Long non-coding RNAs in esophageal cancer: molecular mechanisms, functions, and potential applications
Su, M., Xiao, Y., Ma, J., Cao, D., Zhou, Y., Wang, H., Liao, Q., & Wang, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0663-8 · Cited by 70
Silver-Promoted Desilylation Catalyzed by Ortho- and Allosteric Cucurbiturils
Lu, X., & Masson, E. (2010) · Organic Letters · doi:10.1021/ol100667z · Cited by 71
Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53
DeHart, C. J., Chahal, J. S., Flint, S. J., & Perlman, D. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.030254 · Cited by 70

Authors: Levine, A. J., & Oren, M.
Affiliations: Institute for Advanced Study (US)
Weizmann Institute of Science (IL)
ORCID: Levine, Arnold J.
Oren, Moshe
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-10
Volume: 9
Issue: 10
Pages: 749-758
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2723
PMC: PMC2771725
OpenAlex: W1966163762
Cited by: 1,967
References: 169
Citations by year: 2026: 64 · 2025: 111 · 2024: 107 · 2023: 112 · 2022: 114 · 2021: 129 · 2020: 128 · 2019: 111 · 2018: 127 · 2017: 120 · 2016: 144 · 2015: 115 · 2014: 150 · 2013: 113 · 2012: 170
FWCI: 9.34
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P01CA087497, R37 CA40099, R37CA040099, P01CA87497.)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p53, TP53, tumour suppressor, SV40 large T antigen, transcription factors, cell cycle arrest, apoptosis, cellular senescence, metabolic regulation, cytokine regulation, embryo implantation
MeSH terms: Animals, Humans, Neoplasms, Genes, p53, Tumor Suppressor Protein p53, History, 20th Century, History, 21st Century

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The first 30 years of p53: growing ever more complex.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks